{"generic":"Lanreotide Acetate","drugs":["Lanreotide Acetate","Somatuline Depot"],"mono":{"0":{"id":"jwpfs0","title":"Generic Names","mono":"Lanreotide Acetate"},"1":{"id":"jwpfs1","title":"Dosing and Indications","sub":[{"id":"jwpfs1b4","title":"Adult Dosing","mono":"<ul><li><b>Acromegaly:<\/b> (initial) 90 mg deep SUBQ injection every 4 weeks for 3 months<\/li><li><b>Acromegaly:<\/b> (maintenance) after 3 months, for GH levels greater than 1 ng\/mL but less than or equal to 2.5 ng\/mL, normal insulin-like growth factor-1 (IGF-1), and controlled symptoms, continue 90 mg deep SUBQ every 4 weeks; for GH greater than 2.5 ng\/mL, elevated IGF-1, and\/or uncontrolled symptoms, increase to 120 mg deep SUBQ every 4 weeks; for GH of 1 ng\/mL or less, normal IGF-1, and controlled symptoms, reduce dose to 60 mg deep SUBQ every 4 weeks; thereafter, adjust dose according to response<\/li><li><b>Acromegaly:<\/b> (maintenance) an extended dosing interval of 120 mg deep SUBQ every 6 or 8 weeks may be considered for patients controlled on doses of 60 mg or 90 mg<\/li><li><b>Acromegaly:<\/b> (preoperative treatment) 30 mg IM every 2 weeks for 3 months prior to transsphenoidal surgery, increased to 30 mg IM weekly at week 8 if growth hormone nadir greater than 2.5 mcg\/L, was used in a clinical trial<\/li><li><b>Neuroendocrine tumor, Gastroenteropancreatic:<\/b> 120 mg deep SUBQ injection every 4 weeks<\/li><\/ul>"},{"id":"jwpfs1b5","title":"Pediatric Dosing","mono":"safety and effectiveness in pediatric patients have not been established "},{"id":"jwpfs1b6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment, moderate or severe (acromegaly):<\/b> 60 mg deep SUBQ injection every 4 weeks; after 3 months, adjust dose according to growth hormone (GH) levels, insulin-like growth factor-1 (IGF-1) levels, and control of symptoms; use caution if considering extended dosing interval<\/li><li><b>Renal impairment, mild or moderate (gastroenteropancreatic neuroendocrine tumor):<\/b> No adjustment required<\/li><li><b>Renal impairment, severe (gastroenteropancreatic neuroendocrine tumor):<\/b> Insufficient data to recommend dose<\/li><li><b>Hepatic impairment, moderate or severe (acromegaly):<\/b> 60 mg deep SUBQ injection every 4 weeks; after 3 months, growth hormone (GH) levels, insulin-like growth factor-1 (IGF-1) levels, and control of symptoms; use caution if considering extended dosing interval<\/li><li><b>Hepatic impairment (gastroenteropancreatic neuroendocrine tumor):<\/b> Insufficient data to recommend dose<\/li><li><b>Geriatric:<\/b> No adjustment necessary<\/li><\/ul>"},{"id":"jwpfs1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Acromegaly<\/li><li>Neuroendocrine tumor, Gastroenteropancreatic<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Portal hypertension<br\/>"}]},"3":{"id":"jwpfs3","title":"Contraindications\/Warnings","sub":[{"id":"jwpfs3b9","title":"Contraindications","mono":"Hypersensitivity to lanreotide <br\/>"},{"id":"jwpfs3b10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- Cardiovascular abnormalities, including bradycardia and hypertension, have been reported<\/li><li>-- Use with caution in patients with pre-existing cardiac disorders, as sinus bradycardia may occur, especially during therapy initiation<\/li><li>-- Use with caution in patients with bradycardia<\/li><li>Endocrine and Metabolic:<\/li><li>-- Hypoglycemia or hyperglycemia may occur; monitoring recommended<\/li><li>-- Decreased thyroid function has occurred with therapy, including hypothyroidism; monitoring recommended when clinically indicated<\/li><li>Gastrointestinal:<\/li><li>-- Cholelithiasis may develop due to reduced gallbladder motility; monitoring recommended<\/li><\/ul>"},{"id":"jwpfs3b11","title":"Pregnancy Category","mono":"Lanreotide: C (FDA)<br\/>"},{"id":"jwpfs3b12","title":"Breast Feeding","mono":"Lanreotide: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jwpfs4","title":"Drug Interactions","sub":{"1":{"id":"jwpfs4b14","title":"Major","mono":"<ul><li>Acarbose (theoretical)<\/li><li>Albiglutide (theoretical)<\/li><li>Alogliptin (theoretical)<\/li><li>Canagliflozin (theoretical)<\/li><li>Chlorpropamide (theoretical)<\/li><li>Cyclosporine (theoretical)<\/li><li>Dapagliflozin (theoretical)<\/li><li>Dulaglutide (theoretical)<\/li><li>Empagliflozin (theoretical)<\/li><li>Exenatide (theoretical)<\/li><li>Glimepiride (theoretical)<\/li><li>Glipizide (theoretical)<\/li><li>Glyburide (theoretical)<\/li><li>Insulin (theoretical)<\/li><li>Insulin Aspart, Recombinant (theoretical)<\/li><li>Insulin Bovine (theoretical)<\/li><li>Insulin Degludec (theoretical)<\/li><li>Insulin Detemir (theoretical)<\/li><li>Insulin Glulisine (theoretical)<\/li><li>Insulin Lispro, Recombinant (theoretical)<\/li><li>Linagliptin (theoretical)<\/li><li>Liraglutide (theoretical)<\/li><li>Lixisenatide (theoretical)<\/li><li>Metformin (theoretical)<\/li><li>Miglitol (theoretical)<\/li><li>Nateglinide (theoretical)<\/li><li>Pioglitazone (theoretical)<\/li><li>Pramlintide (theoretical)<\/li><li>Quinidine (theoretical)<\/li><li>Repaglinide (theoretical)<\/li><li>Rosiglitazone (theoretical)<\/li><li>Saxagliptin (theoretical)<\/li><li>Sitagliptin (theoretical)<\/li><li>Terfenadine (theoretical)<\/li><li>Tolazamide (theoretical)<\/li><li>Tolbutamide (theoretical)<\/li><li>Vildagliptin (theoretical)<\/li><\/ul>"}}},"5":{"id":"jwpfs5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Decreased heart rate (23%), Hypertension (5% to 14%)<\/li><li><b>Dermatologic:<\/b>Injection site reaction (9% to 15%)<\/li><li><b>Gastrointestinal:<\/b>Abdominal pain (Acromegaly, 19%; gastroenteropancreatic neuroendocrine tumors, 34%), Diarrhea (37%), Nausea (11%), Vomiting (Acromegaly, 7%; gastroenteropancreatic neuroendocrine tumors, 19%)<\/li><li><b>Musculoskeletal:<\/b>Musculoskeletal pain (19%)<\/li><li><b>Neurologic:<\/b>Dizziness (9%), Headache (7% to 16%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Bradyarrhythmia (1% to 2.8%)<\/li><li><b>Endocrine metabolic:<\/b>Diabetes mellitus, Hyperglycemia (14%), Hypoglycemia, Hypothyroidism (less than 1%)<\/li><li><b>Gastrointestinal:<\/b>Cholelithiasis (12% to 14%), Pancreatitis (less than 1%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis<\/li><li><b>Other:<\/b>Anaphylaxis<\/li><\/ul>"},"6":{"id":"jwpfs6","title":"Drug Name Info","sub":{"0":{"id":"jwpfs6b17","title":"US Trade Names","mono":"Somatuline Depot<br\/>"},"2":{"id":"jwpfs6b19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Somatostatin (class)<\/li><\/ul>"},"3":{"id":"jwpfs6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jwpfs6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jwpfs7","title":"Mechanism Of Action","mono":"Lanreotide acetate, an octapeptide analog of natural somatostatin, behaves similarly to that of natural somatostatin and inhibits secretion of various endocrine, neuroendocrine, exocrine and paracrine functions; thereby, normalizing growth hormones (GH) and\/or insulin-like growth factor-1 (IGF-1) levels in acromegalic patients <br\/>"},"8":{"id":"jwpfs8","title":"Pharmacokinetics","sub":{"0":{"id":"jwpfs8b23","title":"Absorption","mono":"Bioavailability:  73.4% (60 mg), 69% (90 mg), 78.4% (120 mg) <br\/>"},"1":{"id":"jwpfs8b24","title":"Distribution","mono":"Vd: 0.74 L\/kg <br\/>"},"3":{"id":"jwpfs8b26","title":"Excretion","mono":"<ul><li>Fecal: less than 0.5% unchanged<\/li><li>Renal: less than 5%<\/li><li>Total body clearance (hepatic impairment, moderate to severe): 30% decrease (acromegaly); not studied (gastroenteropancreatic neuroendocrine tumors)<\/li><li>Total body clearance (renal impairment): 2-fold decrease (acromegaly); no effect (gastroenteropancreatic neuroendocrine tumors)<\/li><\/ul>"},"4":{"id":"jwpfs8b27","title":"Elimination Half Life","mono":"<ul><li>23 to 30 days<\/li><li>Renal impairment: 2-fold increase (acromegaly)<\/li><li>Healthy elderly: 85% increase<\/li><\/ul>"}}},"9":{"id":"jwpfs9","title":"Administration","mono":"<b>Subcutaneous<\/b><br\/><ul><li>Remove pouch from refrigerator 30 minutes prior to injection; keep pouch sealed until just prior to administration<\/li><li>Inject subQ deeply into the superior external quadrant of the buttock; alternate administration between left and right sides<\/li><\/ul>"},"10":{"id":"jwpfs10","title":"Monitoring","mono":"<ul><li>Acromegaly: growth hormone (GH) and insulin growth factor 1 (IGF-1); 3 months after initiation, periodically during treatment, and 6 weeks after dose adjustments<\/li><li>TSH-secreting adenomas: plasma TSH, free T4, free T3, and lanreotide levels; periodically (Gancel et al, 1994)<\/li><li>Gastroenteropancreatic neuroendocrine tumors: progression free survival may be indicative of efficacy<\/li><li>Acromegaly: Monitor for clinical symptom control with dose adjustments<\/li><li>Blood glucose; initiation of treatment and following dose adjustments<\/li><li>Thyroid function tests; as clinically indicated<\/li><li>Reduced gallbladder motility or gallstone formation; periodically<\/li><\/ul>"},"11":{"id":"jwpfs11","title":"How Supplied","mono":"<b>Somatuline Depot<\/b><br\/>Subcutaneous Solution: 120 MG\/0.5 ML, 90 MG\/0.3 ML, 60 MG\/0.2 ML<br\/>"},"12":{"id":"jwpfs12","title":"Toxicology","sub":[{"id":"jwpfs12b31","title":"Clinical Effects","mono":"<b>OCTREOTIDE AND RELATED AGENTS<\/b><br\/>OVERDOSE: Overdose data are limited with these agents; hypoglycemia, flushing, dizziness and nausea have been reported. ADVERSE EFFECTS: Gastrointestinal adverse effects (eg; anorexia, nausea, vomiting, diarrhea and steatorrhea, constipation, abdominal discomfort, and flatulence) are the most common effects.  Gallstones, hypoglycemia and hyperglycemia, dizziness, pancreatitis, hypothyroidism, sinus bradycardia, conduction abnormalities, dysrhythmias, thrombocytopenia, and hepatitis have also been reported.<br\/>"},{"id":"jwpfs12b32","title":"Treatment","mono":"<b>OCTREOTIDE AND RELATED AGENTS <\/b><br\/><ul><li>Decontamination: Significant toxicity is not anticipated after ingestion because of limited  bioavailability.  Treatment is symptomatic and supportive.  Consider activated charcoal only after very large ingestions.<\/li><li>Hyperglycemia: If significant hyperglycemia occurs, careful blood glucose monitoring and insulin therapy might be required.<\/li><li>Hypoglycemia: Give dextrose if symptomatic or BS &lt;60 mg\/dL. Dose - Adult 50 mL of 50% dextrose IV push; Child 0.5 to 1 g\/kg (2-4 mL\/kg) of 25% dextrose IV push. Feed oral carbohydrates. If recurrent hypoglycemia develops, repeat dextrose bolus and follow with an infusion of 10% dextrose; titrate to a BS of 100 mg\/dL.<\/li><li>Bradycardia: ATROPINE: ADULT DOSE: BRADYCARDIA: 0.5 to 1 mg IV every 5 min. ASYSTOLE: 1 mg IV every 5 min.  Maximum total dose 3 mg or 0.04 mg\/kg.  Minimum single dose 0.5 mg. PEDIATRIC DOSE: 0.02 mg\/kg IV repeat every 5 min, minimum single dose 0.1 mg; maximum single dose child 0.5 mg, adolescent 1 mg; maximum total dose 1 mg child, 2 mg adolescent.<\/li><li>Monitoring of patient: Vital signs, liver enzyme levels, blood glucose level, electrolytes and fluid status, ECG, and continuous cardiac monitoring in symptomatic patients.<\/li><\/ul>"},{"id":"jwpfs12b33","title":"Range of Toxicity","mono":"<b>OCTREOTIDE AND RELATED AGENTS<\/b><br\/>A minimum toxic dose has not been established has not been established for these agents. Overdoses of octreotide up to 120,000 mcg infused over 8 hours have been well tolerated.  Octreotide doses of 2.5 mg (2500 mcg) subcutaneously have caused hypoglycemia, flushing, dizziness, and nausea.<br\/>"}]},"13":{"id":"jwpfs13","title":"Clinical Teaching","mono":"<ul><li>Instruct patient to report cholelithiasis symptoms.<\/li><li>Tell patient to report syncope, weakness, fatigue, or other symptoms of clinically significant bradycardia.<\/li><li>Counsel patient to avoid driving or other activities that require coordination if dizziness occurs.<\/li><li>Side effects may include diarrhea, abdominal pain, nausea, injection site reaction, musculoskeletal pain, vomiting, or headache.<\/li><li>Advise diabetic patients to report worsening glycemic control.<\/li><\/ul>"}}}